| dc.creator |
KORKMAZ, Hakan |
|
| dc.creator |
HEKİMLER ÖZTÜRK, Kuyaş |
|
| dc.creator |
Torus, Bora |
|
| dc.date |
2021-01-01T00:00:00Z |
|
| dc.date.accessioned |
2021-12-03T11:14:44Z |
|
| dc.date.available |
2021-12-03T11:14:44Z |
|
| dc.identifier |
0854e4ff-4edb-4831-bbdf-c51db07176b5 |
|
| dc.identifier |
10.3906/sag-2010-245 |
|
| dc.identifier |
https://avesis.sdu.edu.tr/publication/details/0854e4ff-4edb-4831-bbdf-c51db07176b5/oai |
|
| dc.identifier.uri |
http://acikerisim.sdu.edu.tr/xmlui/handle/123456789/89797 |
|
| dc.description |
Background/aim: miRNAs control various biological functions, such as cell proliferation, differentiation, signaling pathways, apoptosis and metabolism. Recently, it has been shown that there is a relationship between changes in miRNA expression and the development of acromegaly. Studies are needed to identify new disease-specific miRNAs. The aim of the current study is to evaluate plasma miR-29c-3p, miR-31-5p and miR-18a-5p steady-state levels in acromegaly. Another aim is to investigate whether there is a difference in the levels of these miRNAs in patients with inadequate control and controlled acromegaly with somatostatin analog (SSA) therapy. These miRNAs targeting the IGP-1 gene were determined by in silico estimation. |
|
| dc.language |
eng |
|
| dc.rights |
info:eu-repo/semantics/closedAccess |
|
| dc.title |
Circulating miR-29c-3p is downregulated in patients with acromegaly |
|
| dc.type |
info:eu-repo/semantics/article |
|